How a review of the U.S. response to Covid-19 could get started
Outside experts have called for a Sept. 11-style commission to evaluate the U.S. response to the pandemic. Here are some of the issues it could review.
Outside experts have called for a Sept. 11-style commission to evaluate the U.S. response to the pandemic. Here are some of the issues it could review.
A STAT Investigation: Brain biopsies on “vulnerable” patients at Mount Sinai set off alarm bells at FDA, documents show.
Walmart had grand ambitions, back in 2019, to grow a network of cheaper primary care clinics attached to its ubiquitous stores. Those ambitions are now…
Financial strain is created by inequitable health financing structures that overpay private academic medical centers at the expense of safety net hospitals.
A controversial provision of a federal law designed to speed copycat drugs to market and foster competition saved Medicare Part D nearly $15 billion from
“By filing bogus patent listings, pharma companies block competition and inflate the cost of prescription drugs,” said FTC Chair Lina Khan.
As sales slump, the prescription digital therapeutics maker lays off 46% of workforce, and will “evaluate potential strategic alternatives.”
Advocates of a federal ban on menthol cigarettes have spent years trying everything to sway policymakers — now, it seems, they may just have to…
Eli Lilly raised its full-year guidance while it reported strong first-quarter sales of Zepbound, its obesity drug.
In a challenge to the pharmaceutical industry, Doctors Without Borders has revealed the detailed costs of a study it ran for a tuberculosis treatment regimen.
A New Jersey district judge ruled that the Biden administration’s Medicare drug price negotiation program is constitutional